Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection

A herpes virus infection, herpes virus technology, applied in the field of monitoring, treatment and treatment of herpes virus infection in mammals, can solve the problems of not getting enough antiviral treatment, increasing persistent pain, latent infection, etc.

Inactive Publication Date: 2012-06-06
IMMUNEXPRESS
View PDF68 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After 48 hours, there is a risk of getting a false negative test result, as symptoms may start to heal and there is not enough virus on the skin to grow
Four factors independently increased the risk of persistent pain: increasing age, severe or moderately severe pain at the onset of the rash (called acute pain), pain before the onset of the rash (called prodromal pain), and failure to recover within 3 days of the onset of the rash. adequate antiviral therapy
In all cases, initial infection leads to latent infection, and immunocompromised patients are also often at risk of relapse

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection
  • Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection
  • Microarray-mediated diagnosis of herpes virus infection by monitoring host's differential gene expression upon infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0298] Identification of specific diagnostic genes for herpes virus infection

[0299] Experimental Disease Trial Design

[0300] Equine herpesvirus 1 (EHV-1 ) infection was induced in two groups of 13 foals at different times. Six young foals were followed for 20 days (group 1) and infected on day 0 (experimental inoculation). Seven foals were followed for 42 days (group 2) and infected on day 21 (experimental inoculation). All foals were infected with in vitro cultured EHV-1 nasopharyngeal aerosols. Blood samples from group 1 were collected at 8 time points on days 0, 1, 2, 4, 6, 10, 13 and 20. Group 2 blood samples were collected at 16 time points on days 0, 1, 2, 4, 6, 10, 13, 20, 21, 22, 23, 25, 27, 31, 34 and 41. Day 0 samples were used as controls for individual horses.

[0301] Animals of group 2 were then found to have been infected naturally and asynchronously with EHV. All animals in Group 2 were seroconverted, and the time of natural infection was estimated...

Embodiment 2

[0478] Identification of diagnostic marker genes and prioritization of these genes

[0479] For group 1, the differences in gene expression of animals before and after infection with EHV were analyzed according to the empirical Bayes method of Lonnstedt and Speed ​​(Lonnstedt and Speed, 2002, Statistica Sinica, 12: 31-46). The time points after infection were compared with the time points before infection for analysis. Using multiple terms for each animal's effect, the clinical state (before and after EHV infection) terms were fitted to a general linear model by each gene. The genes were ranked according to their posterior odds of differential expression between the clinical status groups. Only those genes with statistically significant changes (assessed with t-statistics based on empirical Bayesian shrunken standard deviation) were recorded. A strong control over the Type 1 error rate was maintained using Holm's correction of p-values ​​(Holm, S., 1979, Scandinavian Journal...

Embodiment 3

[0484] Demonstrated diagnostic potential for assaying herpes virus infection

[0485] Principal component scores calculated from gene expression (Jolliffe, I.T., Principal components analysis, Springer-Verlag, 1986) were analyzed using discriminant analysis (Venables and Ripley, 2002, Statistics in Modern Applications" (Modern Applied Statistics in S, Springer) assessed the diagnostic potential of the entire panel of genes at various time points after infection. The whole method is cross-validated. One animal was dropped at a time for cross-validation (instead of one observation). Both sensitivity and specificity were calculated as uniform prior. This can be interpreted as a form of downscaling, shrinking these estimates into a reduced space.

[0486] Receiver operating curves were estimated using cross-validated discriminant function scores. The receiver operating curve is calculated by shifting the critical threshold along the axis of the discriminant function score. Tw...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses molecule and test about diseases can be used for diagnosing and evaluating the animals infected by herpes virus, and for testing the animals in herpes virus infection or in sequela. The invention allows early diagnosis and monitoring of an infected animal's immune response and thus enables better treatment and management decisions to be made in clinical and sub-clinically affected animals.

Description

field of invention [0001] The present invention generally relates to methods and systems for diagnosing, detecting host response, monitoring, treating and managing herpes virus infection in mammals. The present invention has practical application for early diagnosis of infection, detection of specific immune response to herpes virus infection (with or without clinical symptoms), enabling better treatment and management decisions for clinically and subclinically affected mammals. The invention is also practical for monitoring mammals at risk of developing herpes-related sequelae or recurrence of clinical signs due to latent virus. Such mammals include, but are not limited to, animals that are immunocompromised due to other diseases or administration of therapeutic drugs, chronic fatigue syndrome, stress or exercise training. Background of the invention [0002] Herpesviruses represent a large family of viruses that cause a wide variety of diseases in humans and domestic and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/70C12Q1/68G01N33/48G01N33/50
Inventor R・B・布兰登M・R・托马斯
Owner IMMUNEXPRESS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap